Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL By Ogkologos - June 9, 2026 117 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the frontMIND study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... December 19, 2022 Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular... December 21, 2021 Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions February 16, 2024 EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib August 16, 2024 Load more HOT NEWS Does Eating Processed Meat Increase Your Risk for Cancer? Keeping A Jasmine Plant In Your Room Reduces Anxiety, Panic Attacks... Cancer in My Community: Improving Access to Palliative Care in Indonesia Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults
